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A B S T R A C T   
Introduction: Antibiotic consumption is highest in primary care, and antibiotic overuse furthers antimicrobial 
resistance. In our recently published pilot-RCT, we used monthly aggregated claims data to provide personalized 
antibiotic prescription feedback to general practitioners (GPs). The pilot-RCT has shown that personalized 
prescription feedback is a feasible and promising low-cost intervention to reduce antibiotic prescribing. Here, we 
describe the rationale and design of the follow-up RCT with 3426 GPs in Switzerland. We now have access to 
pseudonymized patient-level data from routinely collected health insurance data of the three largest health in-
surers in Switzerland. 
Methods and analysis: 1713 GPs randomized to the intervention group received once evidence-based treatment 
guidelines at the beginning, including region-specific antibiotic resistance information from the community and 
personalized feedback of their antibiotic prescribing, followed by quarterly personalized prescription feedback for 
two years. The first and the last mailings were sent out in December 2017 and September 2019, respectively. The 
1713 GPs randomized to the control group were not notified about the study and they received no guidelines and 
no prescription feedback. The personalized prescription feedbacks and the analyses of the primary and secondary 
outcomes are entirely based on pseudonymized patient-level data from routinely collected health insurance data. 
The primary outcome is prescribed antibiotics per 100 patient consultations during the second year of intervention. 
The secondary outcomes include antibiotic use during the entire two-year trial period, use of broad-spectrum 
antibiotics, hospitalization rates (all-cause and infection-related), and antibiotic use in different age groups. If 
the feedback intervention proves to be efficacious, the intervention could be continued systemwide. 
Ethics and dissemination: The trial is publicly funded by the Swiss National Science Foundation (SNSF, grant number 
407240_167066). The trial was approved by the ethics committee "Ethikkommission Nordwest-und Zentralschweiz" 
(EKNZ Project-ID 2017-00888). Results will be disseminated in peer-reviewed journals and international conferences.  
List of abbreviations: CI, confidence interval; CONSORT, consolidated standards of reporting trials; DRG, Diagnosis Related Groups; EKNZ, Ethikkommission 
Nordwest-und Zentralschweiz; FMH, Foederatio Medicorum Helveticorum; GP, general practitioners; HRA, Human Research Act; HRO, Human Research Ordinance; 
RCT, randomized controlled trials; ZSR, Zentralregisternummer. 
* Corresponding author. Basel Institute for Clinical Epidemiology and Biostatistics, Department of Clinical Research, University Hospital Basel, CH-4031, Basel, 
Switzerland. 
E-mail addresses: dominik.glinz@usb.ch (D. Glinz), kimberlyalba.deIaco@usb.ch (K.A. Mc Cord), giusi.moffa@unibas.ch (G. Moffa), soheila.aghlmandi@usb.ch 
(S. Aghlmandi), ramon.saccilotto@usb.ch (R. Saccilotto), andreas.zeller@unibas.ch (A. Zeller), andreas.widmer@usb.ch (A.F. Widmer), juliaanna.bielicki@ukbb. 
ch (J. Bielicki), andreas.kronenberg@ifik.unibe.ch (A. Kronenberg), heiner.bucher@usb.ch (H.C. Bucher).  
URL: http://www.ceb-institute.org (H.C. Bucher).  
Contents lists available at ScienceDirect 
Contemporary Clinical Trials Communications 
journal homepage: http://www.elsevier.com/locate/conctc 
https://doi.org/10.1016/j.conctc.2021.100712 
Received 5 August 2020; Received in revised form 26 November 2020; Accepted 12 January 2021   
Contemporary Clinical Trials Communications 21 (2021) 100712
2
1. Background 
Antibiotic resistance is a serious problem worldwide [1] and directly 
related to antibiotic consumption [2–4]. In absolute terms, most anti-
biotics are prescribed in primary care for respiratory and urinary tract 
infections, which represent the most frequent reasons for physician 
contact and antibiotic prescribing [5–8]. 
Strategies to lower antibiotic use in primary care on the system level 
are difficult to implement. Efficacious strategies to reduce antibiotic 
prescribing, like face-to-face education or communication training of 
primary care physicians, are resource-intense, costly, and challenging to 
apply on a large scale [9,10]. Systemwide feedback interventions on 
antibiotic prescribing are less resource-intense and low-cost in-
terventions [11–13]. Only a few randomized controlled trials (RCTs) 
have evaluated feedback interventions for antibiotic prescribing in pri-
mary care. These trials have produced inconsistent results. Two trials 
from the UK, one intervening with a letter from the UK Chief Medical 
Officier to inform general practitioners (GPs) of practices with the 
highest 20% on their high prescribing rates [11], and the second trial, 
sending monthly feedback on antibiotic prescription to GPs for 12 
months, both trials lead to moderate reductions in antibiotic prescribing 
[13]. 
A trial from Australia found no effect on antibiotic prescription rates 
from two feedbacks on antibiotics and other drug prescribing that were 
sent to unselected GPs [14]. In a nationwide trial in Switzerland [12] by 
our group, the provision of quarterly personalized prescription feedback 
to primary care physicians over two years did not result in a reduction of 
antibiotic use (in defined daily doses per 100 consultations) between the 
intervention and the control group (between-group difference: 0.8% in 
the first year; 95%CI -2.6%–4.3%; 1.7% in the second year; − 5.1%– 
1.7%), but reduced prescriptions in predefined subgroups of older 
children and adolescents aged 6–18 years (− 8.6% in the first year; 95% 
CI -14.8% to − 1.9%) and younger adults (− 4.6% in the second year; 
95%CI -7.9% to − 1.2%). 
Switzerland belongs to the countries with the lowest antibiotic 
consumption rates in Europe [15–17]. However, prescriptions of anti-
biotics in primary care are still too high for upper respiratory tract in-
fections, and the high use of quinolone for urinary tract infections is a 
matter of concern [18]. Also, the emergence of multidrug resistance 
remains a problem [19]. 
Here we present the study design of a pragmatic nationwide ran-
domized controlled trial, which assesses a feedback intervention of 
antibiotic prescribing over two years using patient-level data from 
routinely collected health insurance claims data. The use of patient-level 
data will also allow for the monitoring of eventual negative health 
outcomes like reconsultations and hospitalization. Our intervention 
targets primary care physicians in Switzerland with average to high 
antibiotic prescription rates. 
2. Methods/design 
2.1. Study design and objective 
This is a pragmatic randomized controlled trial in primary care 
physicians in Switzerland with average to high antibiotic prescription 
rates. The trial is entirely based on routinely collected individual claims 
data of the three largest Swiss health insurers (Sanitas, CSS, and Hel-
sana) using pseudonymized identifiers of physicians and patients. 
The primary objective is to investigate the effect of a quarterly pre-
scription feedback intervention on the overall antibiotic use in primary 
care in the second year of intervention (long-term effect). Secondary 
objectives are to assess effects on the overall antibiotic use within the 
first 12 months and the entire 24 months intervention duration, and in 
different age groups. Further secondary objectives address the use of 
broad-spectrum antibiotics and the impact of the intervention on the 
eventual unintended effects on hospitalization (all-cause and infection- 
related) and reconsultation rates. 
2.2. Inclusion and exclusion criteria 
We included and use data from board-certified primary care physi-
cians (Foederatio Medicorum Helveticorum, FMH) in Switzerland with 
an individual practicing license number "Zentralregisternummer" (ZSR) 
who are the top 75% prescribers of antibiotic and who have at least 100 
patient contacts per year. Group practices sharing a license number are 
excluded. 
2.3. Study population, sample size, and power analysis 
The data provided by the three health insurers Sanitas, CSS, and 
Helsana, comprise information on a total of 8422 primary care physi-
cians in Switzerland. These primary care physicians treated at least one 
patient covered by one of the three health insurances. Due to the usual 
administrative processing delay of claims data of 6 months by health 
insurers, the definitive sample size calculation had to be based on claims 
data from January to December 2016. In this pre-randomization claims 
data set, we identified 3646 eligible GPs corresponding to the inclusion 
criteria, as mentioned above. A random sample of 220 physicians from 
the Basel area was left aside for a different interventional trial. The 
remaining study population of 3426 physicians were randomized to the 
intervention or control groups, with 1713 physicians in each arm. 
We conducted a power analysis that was based on a trial simulation 
from 50 bootstrap samples. These bootstrap samples were extracted 
from the pool of physicians from the database of the year 2016, which 
was used to select and randomize GPs. The clinically relevant effect that 
the study aims to detect is, on average 5% expected reduction in pre-
scription rates. Therefore, we simulated a trial for each bootstrap sample 
and we applied the effect which we expected to observe in the treatment 
arm. To also account for any variability, we simulated effects from 
distribution of potential effects, which were "centered" around 5%, for 
every physician. The standard deviation of the prescription rate in the 
target population was evaluated based on the data from the year 2016, 
which was 0.059 on the raw scale and 0.438 on the log scale. Also, we 
scaled the distribution to account for the expected proportion of non- 
responders of 15%. For each sample, we then tested the difference 
using a Mann Whitney U test (Wilcoxon rank-sum). Hence, we evaluated 
the power for each bootstrap sample, and derived medians and confi-
dence intervals from the empirical distribution, which gave an estimated 
median power of 0.93 (95% CI: 0.90 to 0.96). 
2.4. Randomization, treatment allocation, and blinding 
All 3426 GPs were randomly allocated by a 1:1 ratio to the inter-
vention and control group using R (R Core Team 2017 [20]). GPs in the 
intervention groups were formally blinded concerning the trial design, 
and GPs in the control group were fully blinded. 
As all RCT relevant data are routinely collected by the automated 
procession of claims data of health insurances, the outcome assessment 
may also be considered as formally blinded. 
Data analysis will be conducted by a statistician blinded for group 
assignment of physicians in the trial. 
2.5. Intervention and control 
The first mailing was sent on December 22, 2017 and was followed 
by seven additional quarterly mailings, with the last mailing sent in late 
September 2019 (see the timeline in Fig. 1). With the first mailing, all 
GPs in the intervention group received (1) an accompanying letter 
explaining the intervention, assuring the full pseudonymization of 
feedback data, (2) a personalized feedback of antibiotic prescribing; (3) 
a response card for physicians wishing to opt-out; and (4) evidence- 
based guidelines on antibiotic prescribing for respiratory and urinary 
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tract infections (see details below). No information on the study design 
or comparative study purpose was provided. 
In the second feedback mailing in April 2018, information on anti-
biotic resistance data and its regional distribution from the Swiss Centre 
for Antibiotic Resistance [19] was added. 
2.6. Personalized antibiotic prescribing feedback 
The personalized antibiotic prescription feedback contained 1) the 
personal yearly prescription rate (antibiotic prescriptions per 100 con-
sultations) compared with the prescription rates of the peer-physicians, 
2) the personal monthly prescription rates for the three months for the 
same period of the preceding year and its comparison with peer- 
physicians (the first feedback mailing was based on antibiotic pre-
scription rates between April 2016 to March 2017), 3) the personal 
yearly prescription rate (antibiotic prescriptions per 100 consultations) 
stratified by type of antibiotics and compared with the prescription rates 
of peer-physicians, and 4) a call to action information in a blue box, 
which varied with each mailing (see example Fig. 2). Personalized 
antibiotic prescription feedback was provided every three months in the 
form of a postal mailing and was continuously updated with the most 
recent complete health insurance data. As there is a six months delay in 
the health insurance billing records processing and the time needed to 
prepare the feedbacks, the yearly prescription feedbacks were based on 
the data from the period of 9 month prior to each sent mailing. All 
information material and guidelines were also made available to phy-
sicians on a password-protected trial website. 
2.7. Evidence-based guidelines 
Evidence-based guidelines for the management of upper and lower 
respiratory tract and urinary tract infections were provided once with 
the first mailing to the GPs in the intervention arm. We updated our 
guidelines from our previous pilot-RCT [12,21] with systematic litera-
ture research for additional evidence on the effectiveness of antibiotics 
for the treatment of these conditions for the time period of 2013 until 
June 2017. Also, we evaluated the literature on the effectiveness of 
relevant diagnostic tests for the identification of bacterial-related upper 
and lower respiratory tract infections in primary care. The guidelines for 
upper respiratory tract infections were updated together with an expert 
group by the Swiss Society of Infectious Diseases that is responsible for 
the development of Swiss national guidelines for the treatment of upper 
respiratory and urinary tract infections. The guidelines were provided as 
a paper brochure with the first mailing at the end of December 2017 to 
all physicians in the intervention group. 
Because more than 90% of physicians’ offices are located in the 
German- and French-speaking regions of Switzerland, we provided all 
information in these two official languages. We assumed that most 
physicians in the Swiss Italian part know either French or German, since 
the Swiss educational system includes German or French, and as there is 
Fig. 1. Time periods when claims data were used for general practitioners selection and randomization, for feedback preparation and intervention, and for baseline 
and outcome assessment. 
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Fig. 2. Example of a antibiotic prescribing feedback form.  
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not yet a medical school in the Swiss Italian part of Switzerland. 
2.8. Outcomes 
The primary outcome is the overall antibiotic use, defined as pre-
scribed antibiotics per 100 patient consultations in the second year of 
intervention lasting from month 13 to month 24 (long-term intervention 
effect). 
The secondary outcomes are (1) overall antibiotic use defined as 
prescribed antibiotics per 100 patient consultations from month 1–12 
(first year of intervention, shorter-term intervention effect); (2) overall 
antibiotic use defined as prescribed antibiotics per 100 patient consul-
tations over the entire intervention period from month 1 to month 24, 
with two repeated measurements, over the first and the second 12 
month period of intervention; (3) use of broad-spectrum antibiotics 
(quinolones and oral cephalosporines) per 100 patient consultations; (4) 
hospitalizations rates (all-cause and related to infections based on 
Diagnosis Related Groups (DRG) definition); (5) Antibiotic use (pre-
scribed antibiotics per 100 patient consultations) in five specific age 
groups, in patients 0–14 years, 15–24 years, 25–54 years, 55–64 years, 
and ≥65 years; and (6) secondary outcomes (3) to (5) will be evaluated 
separately over the second and first 12 months (from month 13 to month 
24 and 1–12 months). 
All cause hospitalization will be defined as any hospitalization (DRG- 
based) within 30 days after a preceeding GP consulation. Infection- 
related hospitalization will be defined as any hospitalization within 30 
days after a preceeding GP consulation with DRG-codes for community 
acquired pneumonia, urinary sepsis, or sepsis. Reconsultation will be 
defined as any consultation within 30 days after a first GP consultation 
or any emergency consultation in a hospital. 
2.9. Data source and privacy 
This RCT is entirely based on routinely collected claims data. The 
data extracted and used for this trial are provided by the three Swiss 
health insurers Sanitas, CSS, and Helsana using the physicians’ license 
number ("Zentralregisternummer" i.e. ZSR number). The ZSR number is 
centrally distributed and provided for all licensed physicians in 
Switzerland by SASIS/Santésuisse. The information are pseudonymized 
in the data to ensure confidentiality of records not allowing to identify 
individual physicians or their patients or the health insurer by the trial 
investigators. Based on the ZSR numbers, the coordinating data manager 
from one (Sanitas) of the three health insurers created a unique identi-
fier for each GP. The unique GP identifier allows for the analysis of 
pseudonymized claims data per physician and per patient, but these 
identifiers cannot be linked to ZSR numbers by the study investigators or 
the study staff at any time. 
Quarterly prescription feedbacks were prepared by one trial statis-
tician not further involved in the analysis, and printed and packaged by 
staff not otherwise involved in the trial. Physicians’ unique pseudony-
mous identifiers could be seen in the window of letter envelops con-
taining personalized prescription feedback. The physicians’ address was 
then stuck on the window of the envelope by an independent person not 
involved in the trial who was in possession of a list of all physician’s 
addresses and the unique pseudonymous identifier. This list was kept on 
a different password-protected server that could not be accessed by any 
other person. 
The specified study datasets are securely transferred in encrypted 
format from health insurers to the study server at University Hospital 
Basel. Study data are stored and processed on infrastructure located 
within the University Hospital Basel. Data management was conducted 
in accordance with the procedures used for trial data management by 
the clinical trial unit. Access to the dataset is strictly limited to the data 
manager and the statistician of the project. 
2.10. Claims database 
Claims data was formatted by data managers of all three health in-
surers according to a protocol in a standardized fashion that allowed for 
data import and the identification of the relevant physician population, 
the generation of the antibiotic prescribing feedbacks and for the gen-
eration of the full claims data set for the final analysis. The relevant 
variables of claims data can be grouped into five categories, physician 
identifiers and demographics (Table 1 a)), patient identifier and de-
mographics (Table 1 b)), consultation data including the primary 
outcome data of antibiotic prescribing (Table 1c)), claims consultation 
data with relevant diagnostic test ordering, prescribing of all medication 
(pharmacy costing groups) (Table 1 d)), and hospitalization data 
(Table 1 e)). Due to the size of the data, only data sets 1a) to 1c), were 
provided by insurers for the intervention phase (generation of person-
alized prescribing feedback) of the trial. By the nature of claims data 
(administrative data), we expected very few missing data, hence, no 
specific procedure to handle missing data is planned. 
2.11. Data analysis 
Statistical analysis will be performed by the trial statistician using R 
(R Core Team 2017 [20]). All analyses will be conducted using the final 
dataset, which will be available in September 2020 (see also timeline in 
Fig. 1C) and will follow CONSORT guidelines and intention-to-treat 
principles [22–24]. A flowchart will describe the inclusion and 
follow-up of GPs by study arm. Baseline characteristics will be described 
by study arm with summary statistics such as median and interquartile 
range or number and percentage; no formal testing between arms will be 
performed [25]. Outcomes will be described by arm using summary 
statistics. 
The primary outcome, the proportion of individuals with an 
Table 1 
Description of routinely collected data – basic information of primary care 
physician and consulations  
Variable groups Description of variables 
Table 1a) Physician identifier and demographics 
Physician identifier Encrypted number (pseudonymized ZSR number) 
Canton Location of the practice (Swiss cantons) 
Speciality General internal medicine, pediatrics or family doctor 
Table 1b) patient identifier and demographics 
Patient Identifier Encrypted number (pseudonymized from health 
insurerdatabases) 
Age category (in 2017) For years 0–5; 6–10; 11–15; in 5-year categories up to 
registered maximum age 
Majority Yes/no 
Gender Male, female 
Insurance membership 
Identifier 
Pseudonymized codes for the three health insurers 
Table 1c) consultation data including the primary outcome data of antibiotic 
prescribing 
Consultation Date of consultation, specific Tarmed code(s) and total 
number of Tarmed code(s) 
Table 1d) claims consultation data with relevant diagnostic test ordering, prescribing 
of all medication (pharmacy costing groups) 
Diagnostic Date of laboratory analysis, code(s) from the list of 
laboratory analyses 
Pharmacy-Cost groups Date of the prescription, complete ATC code, total 
number of prescriptions in ATC group, total costs 
according to claims in CHF, costs per package 
Antibiotics Date of the prescription, all pharma codes from ATC 
group J01, complete ATC code (ATC group J01), number 
of prescribed packages, total costs according to claims in 
CHF, costs per packages in CHF 
Table 1e) Inpatient information 
Hospitalization Date of hospital admission, date of hospital discharge, 
DRG code(s)  
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antibiotic prescription in the second year of the intervention, will be 
assessed by ANCOVA modeling, with the outcome as a response, inter-
vention (yes/no) as a factor of interest, and baseline year antibiotic 
prescription rate as a covariate (the baseline year is January–December 
2017). Other baseline covariates of interest include comorbidities 
(based on pharmacy cost groups) patients’ age, annual patient volume 
(total number of consultations per GP), and seasonality. For the primary 
outcome analysis, the coefficient estimates and their 95% CI will be 
reported. Secondary outcomes will be evaluated in the same way. 
Effects for the period month 1 to month 24 will be modeled using a 
linear mixed model including the intervention (yes/no), time (baseline, 
first year, second year), an interaction term for the intervention with 
time, and by treating physician as random effects. Mean percentage 
changes from baseline will be derived for the intervention and control 
groups. Other baseline covariates of interest will be included as for the 
primary analysis. 
The rates of hospitalizations and reconsultations will be modeled 
using logistic regressions including the intervention as a factor of in-
terest and other relevant covariates. Hospitalization rates in the inter-
vention and control group, with exact 95% CIs will be reported, and 
odds ratios for the intervention arm vs. control will be derived from the 
coefficients estimated for the logistic regression model. 
The analysis in specific age groups will be similar to the primary 
analysis over the respective periods and stratified by age groups i) 0–14 
years, ii) 15–24 years, iii) 25–54 years, iv) 55–64 years, and v) 65 years 
and over. 
2.12. Ethics and dissemination 
The study trial protocol was approved by the lead ethics committee 
Ethikkommission Nordwest-und Zentralschweiz (EKNZ Project-ID 2017- 
00888) according to the simplified approval procedure based on Art. 34 
"Absence of informed consent" of the Human Research Act (HRA) and 
based on Art. 37–40 "Use of Biological Material and Health-Related 
Personal Data for Research in the Absence of Informed Consent" of the 
Human Research Ordinance (HRO). Without further requests by the lead 
ethics committee, the approval of the lead ethics committee is valid for 
all remaining cantons of Switzerland. 
3. Discussion 
To our knowledge, this is the first pragmatic RCT using routinely 
collected patient level claims data to assess the effects of quarterly 
personalized prescription feedback on antibiotic prescribing in primary 
care on the national health system level. In our pilot RCT [12,21], 
feedbacks and final analyses were based on monthly aggregated claims 
data, and not on patient-level data. As a consequence, the analyses, 
including subgroups, were limited because of the aggregated nature of 
the data. Built on the experience of the pilot RCT, we planned the pre-
sent trial protocol using patient-level data from routinely collected 
claims data. For instance, a more comprehensive quarterly feedback to 
GPs (prescribing rates instead of defined daily doses) and the 
patient-level data will allow for more detailed analyses of antibiotic 
prescribing patterns and to correlate them for example with test 
ordering like CRP, pharyngeal swabs or urine cultures. 
Moreover, patient-level data allows for investigating multiple anti-
biotic prescribing in the same patient and the analysis of potentially 
unintended consequences of the intervention like hospitalization, 
emergency ward consultations, and reconsultations due to untreated 
bacterial infections. We will also receive detailed data on ordering of 
diagnostic laboratory tests, X-rays and referals to specialists that are 
relevant for the management of respiratory and urinary tract infections. 
This will allow for secondary analysis of physician practice patterns and 
antibiotic prescribing and provide useful data for the planned health 
economic analyses. 
3.1. Strengths and limitations 
Our pragmatic trial design will allow to generate evidence of high 
internal and external validity on the effectiveness of antibiotic pre-
scribing feedback in primary care, due to the randomized trial design 
and blinding for the nature of the intervention, and the use of routinely 
collected claims data, which assures continuous and complete follow-up 
data with no interference with daily routine for data collection. Full 
blinding of the control group by use of Zelen’s design [26] allows for a 
comparator that reflects the actual practice of antibiotic prescribing in 
primary care in Switzerland at large. If our feedback intervention proves 
to be efficacious, the intervention could be continued systemwide as the 
infrastructure has been established for the purpose of this trial. This 
would allow continuous monitoring of antibiotic prescribing at low costs 
and to intervene if peer-based prescribing benchmarks are constantly 
overrun by some GPs. 
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